- Home
- WIT vs GH Comparison
WIT vs GH Comparison
Compare WIT & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WIT | GH |
|---|---|---|
| Founded | 1945 | 2011 |
| Country | India | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.0B | 22.9B |
| IPO Year | 2000 | 2018 |
Fundamental Metrics
Financial Performance| Metric | WIT | GH |
|---|---|---|
| Price | $1.70 | $176.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 19 |
| Target Price | N/A | ★ $119.79 |
| AVG Volume (30 Days) | ★ 8.9M | 1.7M |
| Earning Date | 04-16-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.42% | N/A |
| EPS Growth | N/A | ★ 6.74 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $982,021,000.00 |
| Revenue This Year | $10.20 | $33.30 |
| Revenue Next Year | $4.98 | $28.27 |
| P/E Ratio | $16.59 | ★ N/A |
| Revenue Growth | N/A | ★ 32.88 |
| 52 Week Low | $1.65 | $55.38 |
| 52 Week High | $3.09 | $183.51 |
Technical Indicators
Market Signals| Indicator | WIT | GH |
|---|---|---|
| Relative Strength Index (RSI) | 39.52 | 53.82 |
| Support Level | $1.65 | $153.88 |
| Resistance Level | $1.79 | $173.94 |
| Average True Range (ATR) | 0.04 | 8.23 |
| MACD | -0.00 | 0.82 |
| Stochastic Oscillator | 28.21 | 56.78 |
Price Performance
Historical ComparisonAbout WIT Wipro Limited
Wipro is a multinational IT services provider based in Bengaluru, India. The company pivoted into the IT space in the 1980s and grew into one of the largest Indian IT consulting companies during the dot-com boom. Nowadays, Wipro leverages its offshore outsourcing model to derive a significant portion of its revenue from North America and Europe.
About GH Guardant Health Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.